Janice L. Pasieka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Janice L. Pasieka has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Lloyd A. Mack
University of Calgary and the Tom Baker Cancer Centre
2 shared publicationsOtto Rorstad
Endocrine Tumour Oncology Group Tom Baker Cancer Centre and University of Calgary Calgary Alberta Canada
2 shared publicationsAlexander McEwan
Department of Nuclear Medicine Cross Cancer Institute and University of Alberta Edmonton Alberta Canada
1 shared publicationAnthony J. Chambers
1 shared publicationBeth Krzywda
Department of Surgery Division of General Surgery Medical College of Wisconsin 9200 West Wisconsin Avenue Milwaukee Wisconsin 53226 USA<!--USA--
1 shared publicationElijah. Dixon
Department of Surgery, Division of General Surgery, Foothills Medical Center, University of Calgary, Calgary, Alberta, Canada
1 shared publication
Latest Publications
- 16 March 2009
- Published by Wiley in World Journal of Surgery
- Vol. 33 (11) , 2244-2255
What Symptom Improvement Can Be Expected After Operation for Primary Hyperparathyroidism?
Background: The only cure for primary hyperparathyroidism (pHPT) is operative resection of the parathyroid gland(s) responsible for the disease. The 1990 National Institute of Health’s (NIH) consensus development conference on asymptomatic pHPT and its subsequent workshop in 2001 established which clinical criteria warranted parathyroidectomy (PTx) versus observation. While there is no debate that these NIH criteria capture a group of patients likely to benefit from PTx, there is concern that these guidelines miss a significant percentage of pHPT patients who actually are symptomatic. Unfortunately, these additional symptoms are often subtle, nonspecific, not traditionally measured, frequently not assessed or considered in this patient population, and are usually attributed to other diagnoses or simply advanced age.Methods: An evidence‐based literature review was performed assessing symptoms and clinical conditions associated with bone, neuropsychiatry, cognition, quality of life, and the neuromuscular system. The level of evidence and grade of recommendations were assigned to key studies to help determine recommendations regarding indications and potential benefits of parathyroidectomy (PTx).Results: Symptoms ranging from decreased bone mineral density, increased fracture risk, neuropsychiatric symptoms and cognitive changes, lower quality of life, and neuromuscular symptoms were found to be associated with pHPT. The effects of PTx on these symptoms was addressed in a variety of studies that varied in quality.Conclusion: Although there are few Level I randomized clinical trials addressing the benefit of PTx in patients with pHPT, there are supportive data to suggest that most patients with pHPT would benefit from operative cure.
- 16 March 2009
- Published by Wiley in World Journal of Surgery
- Vol. 33 (11) , 2244-2255
What Symptom Improvement Can Be Expected After Operation for Primary Hyperparathyroidism?
Background: The only cure for primary hyperparathyroidism (pHPT) is operative resection of the parathyroid gland(s) responsible for the disease. The 1990 National Institute of Health’s (NIH) consensus development conference on asymptomatic pHPT and its subsequent workshop in 2001 established which clinical criteria warranted parathyroidectomy (PTx) versus observation. While there is no debate that these NIH criteria capture a group of patients likely to benefit from PTx, there is concern that these guidelines miss a significant percentage of pHPT patients who actually are symptomatic. Unfortunately, these additional symptoms are often subtle, nonspecific, not traditionally measured, frequently not assessed or considered in this patient population, and are usually attributed to other diagnoses or simply advanced age.Methods: An evidence‐based literature review was performed assessing symptoms and clinical conditions associated with bone, neuropsychiatry, cognition, quality of life, and the neuromuscular system. The level of evidence and grade of recommendations were assigned to key studies to help determine recommendations regarding indications and potential benefits of parathyroidectomy (PTx).Results: Symptoms ranging from decreased bone mineral density, increased fracture risk, neuropsychiatric symptoms and cognitive changes, lower quality of life, and neuromuscular symptoms were found to be associated with pHPT. The effects of PTx on these symptoms was addressed in a variety of studies that varied in quality.Conclusion: Although there are few Level I randomized clinical trials addressing the benefit of PTx in patients with pHPT, there are supportive data to suggest that most patients with pHPT would benefit from operative cure.
- 10 July 2007
- Published by Springer Nature in Clinical & Translational Metabolism
- Vol. 5 (2) , 122-128
The Spectrum of Clinical Benefits Following Parathyroidectomy for Primary Hyperparathyroidism
- 10 July 2007
- Published by Springer Nature in Clinical & Translational Metabolism
- Vol. 5 (2) , 122-128
The Spectrum of Clinical Benefits Following Parathyroidectomy for Primary Hyperparathyroidism
- 27 April 2007
- Published by Wiley in World Journal of Surgery
- Vol. 31 (6) , 1194-1195
Invited commentary
- 27 April 2007
- Published by Wiley in World Journal of Surgery
- Vol. 31 (6) , 1194-1195
Invited commentary
- 15 January 2007
- Published by Wiley in World Journal of Surgery
- Vol. 31 (5) , 978-986
An Evidence‐Based Approach to the Treatment of Thyroid Lymphoma
Background: Primary thyroid lymphoma is a rare tumor that makes up 1–5% of thyroid malignancies and less than 2% of extranodal lymphomas. The treatment and prognosis of thyroid lymphomas can be divided into two distinct clinicopathologic entities: pure mucosa‐associated lymphoid tissue (MALT) lymphomas and diffuse large B‐cell or mixed subtypes.Methods: An evidence‐based review was performed to determine the role of fine‐needle aspiration (FNA) biopsy and adjuncts as the first diagnostic test for thyroid lymphoma, the role of open surgical biopsy, the role of palliative surgery as well as the best treatment (combined chemoradiation versus single modality surgery or radiation) for thyroid lymphoma. The ideal treatment of thyroid lymphoma was further assessed for both diffuse B‐cell and MALT histologic subtypes.Results: Although an evidence‐based review was challenging primarily due to a lack of high‐level evidence, several recommendations are possible and presented regarding the optimal diagnostic methods and treatment of thyroid lymphoma. FNA and adjuncts are recommended as the first test to diagnose thyroid lymphoma, but open surgical biopsy may still be required in many cases. Combined chemoradiation therapy is recommended for all diffuse B‐cell or mixed lymphomas. Single modality therapy with surgery or radiation alone may be considered for early‐stage (IE) intrathyroidal MALT lymphomas. No recommendations could be made regarding the role of palliative surgery.Conclusion: Evidence‐based recommendations can be applied to the individual patient with thyroid lymphoma with the involvement of an experienced multidisciplinary team consisting of an endocrine/oncology surgeon, radiation oncologist, and medical oncologist.
- 15 January 2007
- Published by Wiley in World Journal of Surgery
- Vol. 31 (5) , 978-986
An Evidence‐Based Approach to the Treatment of Thyroid Lymphoma
Background: Primary thyroid lymphoma is a rare tumor that makes up 1–5% of thyroid malignancies and less than 2% of extranodal lymphomas. The treatment and prognosis of thyroid lymphomas can be divided into two distinct clinicopathologic entities: pure mucosa‐associated lymphoid tissue (MALT) lymphomas and diffuse large B‐cell or mixed subtypes.Methods: An evidence‐based review was performed to determine the role of fine‐needle aspiration (FNA) biopsy and adjuncts as the first diagnostic test for thyroid lymphoma, the role of open surgical biopsy, the role of palliative surgery as well as the best treatment (combined chemoradiation versus single modality surgery or radiation) for thyroid lymphoma. The ideal treatment of thyroid lymphoma was further assessed for both diffuse B‐cell and MALT histologic subtypes.Results: Although an evidence‐based review was challenging primarily due to a lack of high‐level evidence, several recommendations are possible and presented regarding the optimal diagnostic methods and treatment of thyroid lymphoma. FNA and adjuncts are recommended as the first test to diagnose thyroid lymphoma, but open surgical biopsy may still be required in many cases. Combined chemoradiation therapy is recommended for all diffuse B‐cell or mixed lymphomas. Single modality therapy with surgery or radiation alone may be considered for early‐stage (IE) intrathyroidal MALT lymphomas. No recommendations could be made regarding the role of palliative surgery.Conclusion: Evidence‐based recommendations can be applied to the individual patient with thyroid lymphoma with the involvement of an experienced multidisciplinary team consisting of an endocrine/oncology surgeon, radiation oncologist, and medical oncologist.
- 27 November 2006
- Published by Wiley in Journal of Surgical Oncology
- Vol. 94 (8) , 725-736
Anaplastic thyroid cancer and primary thyroid lymphoma: A review of these rare thyroid malignancies
Background: To review the current literature on the treatment of anaplastic thyroid cancer (ATC) and thyroid lymphoma (TL).Results: Both anaplastic carcinoma (ATC) and TL represent rare forms of thyroid cancer. ATC behaves in a highly aggressive manner, resulting in significant morbidity and mortality. Multimodality therapy consisting of both radiotherapy (RT) and chemotherapy is essential in obtaining local/regional control. Although ATC has been relatively chemo resistant, newer agents such like taxotere show promise. The role of surgery in the treatment of ATC continues to evolve, presently it should be reserved for patients who have shown an initial response to multimodality therapy and in patients in whom a complete macroscopic resection can be achieved with minimal morbidity. The successful treatment of TL currently lies in accurately diagnosing the histological subtype. Both large B‐cell and mixed lymphomas are best treated with multimodality therapy consisting of CHOP combined with hyper‐fractioned RT. MALT lymphomas with there more indolent course may be amenable to single modality RT or total thyroidectomy if diagnosed at an early stage IE.Discussion: Although both ATC and TL are rare, it is important for surgeons to be aware of the need for multimodality therapy when treating these patients and to understand the limited role surgery plays in diagnosis and treatment. J. Surg. Oncol. 2006;94:725–736.
- 27 November 2006
- Published by Wiley in Journal of Surgical Oncology
- Vol. 94 (8) , 725-736
Anaplastic thyroid cancer and primary thyroid lymphoma: A review of these rare thyroid malignancies
Background: To review the current literature on the treatment of anaplastic thyroid cancer (ATC) and thyroid lymphoma (TL).Results: Both anaplastic carcinoma (ATC) and TL represent rare forms of thyroid cancer. ATC behaves in a highly aggressive manner, resulting in significant morbidity and mortality. Multimodality therapy consisting of both radiotherapy (RT) and chemotherapy is essential in obtaining local/regional control. Although ATC has been relatively chemo resistant, newer agents such like taxotere show promise. The role of surgery in the treatment of ATC continues to evolve, presently it should be reserved for patients who have shown an initial response to multimodality therapy and in patients in whom a complete macroscopic resection can be achieved with minimal morbidity. The successful treatment of TL currently lies in accurately diagnosing the histological subtype. Both large B‐cell and mixed lymphomas are best treated with multimodality therapy consisting of CHOP combined with hyper‐fractioned RT. MALT lymphomas with there more indolent course may be amenable to single modality RT or total thyroidectomy if diagnosed at an early stage IE.Discussion: Although both ATC and TL are rare, it is important for surgeons to be aware of the need for multimodality therapy when treating these patients and to understand the limited role surgery plays in diagnosis and treatment. J. Surg. Oncol. 2006;94:725–736.
- 17 February 2005
- Published by Wiley in Journal of Surgical Oncology
- Vol. 89 (3) , 202-205
Kindred spirits of the endocrines: The training of the future endocrine surgeons
The growth of knowledge and complexity now seen in General Surgery, has led to the sub‐specialization of the discipline. Although it is considered by some to have led to the fragmentation of General Surgery and the erosion of the specialty as we know it today, others would argue that it has and will continue to lead to a stronger division and a higher standard of care. Most would argue that a higher standard of care in focus areas stimulates research and research, in turn, improves the quality of education and training. Ultimately, improved education and training leads to better patient care. Organ‐specific specialization such as orthopedics and urology evolved from General Surgery and demonstrates this principle. Further sub‐specialization is likely inevitable, if the discipline of General Surgery is to remain a desired specialty. Endocrine surgery has evolved into a sub‐specialty of General Surgery, and over the last few decades has matured as a discipline. With this maturation comes the responsibility of defining the standard of care to be provided by surgeons involved in endocrine surgery. To achieve this goal, endocrine surgical associations and societies must set the standard of training both at the residency and postgraduate level. Where we are as a sub‐specialty, where we came from, and what it will take to meet this goal are discussed. J. Surg. Oncol. 2005;89:202–205.
- 17 February 2005
- Published by Wiley in Journal of Surgical Oncology
- Vol. 89 (3) , 202-205
Kindred spirits of the endocrines: The training of the future endocrine surgeons
The growth of knowledge and complexity now seen in General Surgery, has led to the sub‐specialization of the discipline. Although it is considered by some to have led to the fragmentation of General Surgery and the erosion of the specialty as we know it today, others would argue that it has and will continue to lead to a stronger division and a higher standard of care. Most would argue that a higher standard of care in focus areas stimulates research and research, in turn, improves the quality of education and training. Ultimately, improved education and training leads to better patient care. Organ‐specific specialization such as orthopedics and urology evolved from General Surgery and demonstrates this principle. Further sub‐specialization is likely inevitable, if the discipline of General Surgery is to remain a desired specialty. Endocrine surgery has evolved into a sub‐specialty of General Surgery, and over the last few decades has matured as a discipline. With this maturation comes the responsibility of defining the standard of care to be provided by surgeons involved in endocrine surgery. To achieve this goal, endocrine surgical associations and societies must set the standard of training both at the residency and postgraduate level. Where we are as a sub‐specialty, where we came from, and what it will take to meet this goal are discussed. J. Surg. Oncol. 2005;89:202–205.
- 17 February 2005
- Published by Wiley in Journal of Surgical Oncology
- Vol. 89 (3) , 105-107
Endocrine surgery: Our current understanding of the treatment and the controversies within this diverse group of tumors
- 17 February 2005
- Published by Wiley in Journal of Surgical Oncology
- Vol. 89 (3) , 105-107
Endocrine surgery: Our current understanding of the treatment and the controversies within this diverse group of tumors
- 28 October 2004
- Published by Wiley in World Journal of Surgery
- Vol. 28 (11) , 1157-1162
131I‐Meta‐iodobenzylguanidine in the Management of Metastatic Midgut Carcinoid Tumors
The management of metastatic neuroendocrine tumors incorporates multimodal therapy with surgery, biotherapy, and chemotherapy. Tumor-targeted therapies using radiolabeled octreotide and meta-iodobenzylguanidine (mIBG) represent a novel treatment approach. The aim of this study was to evaluate the effectiveness of 131I-mIBG in the treatment of metastatic midgut carcinoid tumors. survival outcomes were assessed for patients treated at two regional cancer centers and then compared. One center used 131I-mIBG routinely in the management of metastatic carcinoid tumors (center A), and the other did not use this modality (center B). Only patients with histologically proven metastatic carcinoid tumor shown, or thought most likely, to be of midgut origin were included in the study. During the period 1980 to 2002, a series of 58 patients from center A with metastatic carcinoid tumor arising from the midgut underwent multimodality therapy with the addition of 131I-mIBG. Their median age was 64 years. The median dose of 131I-mIBG administered was 6751 MBq, and there was an average of 2.8 treatments per patient. During the same period, 58 patients with metastatic carcinoid were treated at center B with similar multimodality therapy without the use of 131I-mIBG therapy. Their median age was 65 years. Survivals at 3 and 5 years were 77% and 63%, respectively (95% CI 47–75), for group A. The 3- and 5-year survivals for group B were 56% and 47% (95% CI 34–59), respectively. The mean follow-up was 6.6 years for group A and 5.0 years for group B. Although retrospective in nature, this study suggests that the addition of 131I-mIBG therapy to the treatment protocol of patients with metastatic midgut carcinoid tumors prolongs survival.
- 28 October 2004
- Published by Wiley in World Journal of Surgery
- Vol. 28 (11) , 1157-1162
131I‐Meta‐iodobenzylguanidine in the Management of Metastatic Midgut Carcinoid Tumors
The management of metastatic neuroendocrine tumors incorporates multimodal therapy with surgery, biotherapy, and chemotherapy. Tumor-targeted therapies using radiolabeled octreotide and meta-iodobenzylguanidine (mIBG) represent a novel treatment approach. The aim of this study was to evaluate the effectiveness of 131I-mIBG in the treatment of metastatic midgut carcinoid tumors. survival outcomes were assessed for patients treated at two regional cancer centers and then compared. One center used 131I-mIBG routinely in the management of metastatic carcinoid tumors (center A), and the other did not use this modality (center B). Only patients with histologically proven metastatic carcinoid tumor shown, or thought most likely, to be of midgut origin were included in the study. During the period 1980 to 2002, a series of 58 patients from center A with metastatic carcinoid tumor arising from the midgut underwent multimodality therapy with the addition of 131I-mIBG. Their median age was 64 years. The median dose of 131I-mIBG administered was 6751 MBq, and there was an average of 2.8 treatments per patient. During the same period, 58 patients with metastatic carcinoid were treated at center B with similar multimodality therapy without the use of 131I-mIBG therapy. Their median age was 65 years. Survivals at 3 and 5 years were 77% and 63%, respectively (95% CI 47–75), for group A. The 3- and 5-year survivals for group B were 56% and 47% (95% CI 34–59), respectively. The mean follow-up was 6.6 years for group A and 5.0 years for group B. Although retrospective in nature, this study suggests that the addition of 131I-mIBG therapy to the treatment protocol of patients with metastatic midgut carcinoid tumors prolongs survival.
- 1 August 2004
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 5 (4) , 307-313
Primary thyroid lymphomas
Primary thyroid lymphoma is a rare disease that continues to produce diagnostic and therapeutic dilemmas. There was great difficulty in distinguishing thyroid lymphoma from anaplastic thyroid carcinoma but, because of new immunocytochemical staining techniques and increased cytopathologic knowledge, our ability to diagnose thyroid lymphoma has improved drastically over the past decade. Surgery that was once the mainstay of treatment for this disease, now plays a minimal role. Current treatment regimens for primary thyroid lymphoma consist of chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) and external beam radiation. The overall and distant relapse rates have been shown to be significantly lower in those patients receiving combined modality therapy compared to chemotherapy or radiation alone. Although the role of surgery has changed over time, it continues to play an important role, especially in confirming diagnoses through open biopsies, potentially providing local control in the more indolent subtypes, and may play a role in the palliation of symptoms for large obstructive lymphomas. The evolving classification of extranodal lymphomas has brought about a better understanding of the biologic behavior of these tumors. Most thyroid lymphomas are B-cell origin, with six different histologic subtypes, but there appears to be two distinct clinical and prognostic groupings of these rare tumors. The more indolent lymphomas are the subgroup of mucosa-associated lymphoid tissue (MALT) lymphomas comprising approximately 6% to 27% of thyroid lymphomas. This subgroup, when localized to the thyroid (stage IE), responds well to total thyroidectomy or radiation with a complete response rate of more than 90%, leading some authors to recommend surgery as primary therapy in the treatment of localized MALT lymphomas. Therefore, surgery as a primary treatment for thyroid lymphomas would only be recommended under ideal conditions, such as MALT subtype stage IE only, and completely resectable with minimal morbidity. Unfortunately, this scenario is rarely the case. The more common subtype, comprising up to 70% of cases, is diffuse large B-cell lymphoma. This subtype appears to have the most aggressive clinical course with almost 60% of these tumors diagnosed with disseminated disease. Up to 40% of all diffuse large cell lymphomas appear to have undergone transformation from a MALT lymphoma, but they behave in a similar fashion to diffuse large cell lymphomas. Treatment for these tumors should include chemotherapy and radiation. The overall 5-year survival for this aggressive group is less then 50%. Surgery is rarely beneficial in diffuse large cell lymphoma and the mixed large cell subtypes because the disease is generally disseminated and surgical excision of all disease is not possible or associated with increased morbidity. However, there may be a role for palliative surgical debulking to alleviate obstructive symptoms while the patient is undergoing standard chemotherapy and radiation.
- 1 August 2004
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 5 (4) , 307-313
Primary thyroid lymphomas
Primary thyroid lymphoma is a rare disease that continues to produce diagnostic and therapeutic dilemmas. There was great difficulty in distinguishing thyroid lymphoma from anaplastic thyroid carcinoma but, because of new immunocytochemical staining techniques and increased cytopathologic knowledge, our ability to diagnose thyroid lymphoma has improved drastically over the past decade. Surgery that was once the mainstay of treatment for this disease, now plays a minimal role. Current treatment regimens for primary thyroid lymphoma consist of chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) and external beam radiation. The overall and distant relapse rates have been shown to be significantly lower in those patients receiving combined modality therapy compared to chemotherapy or radiation alone. Although the role of surgery has changed over time, it continues to play an important role, especially in confirming diagnoses through open biopsies, potentially providing local control in the more indolent subtypes, and may play a role in the palliation of symptoms for large obstructive lymphomas. The evolving classification of extranodal lymphomas has brought about a better understanding of the biologic behavior of these tumors. Most thyroid lymphomas are B-cell origin, with six different histologic subtypes, but there appears to be two distinct clinical and prognostic groupings of these rare tumors. The more indolent lymphomas are the subgroup of mucosa-associated lymphoid tissue (MALT) lymphomas comprising approximately 6% to 27% of thyroid lymphomas. This subgroup, when localized to the thyroid (stage IE), responds well to total thyroidectomy or radiation with a complete response rate of more than 90%, leading some authors to recommend surgery as primary therapy in the treatment of localized MALT lymphomas. Therefore, surgery as a primary treatment for thyroid lymphomas would only be recommended under ideal conditions, such as MALT subtype stage IE only, and completely resectable with minimal morbidity. Unfortunately, this scenario is rarely the case. The more common subtype, comprising up to 70% of cases, is diffuse large B-cell lymphoma. This subtype appears to have the most aggressive clinical course with almost 60% of these tumors diagnosed with disseminated disease. Up to 40% of all diffuse large cell lymphomas appear to have undergone transformation from a MALT lymphoma, but they behave in a similar fashion to diffuse large cell lymphomas. Treatment for these tumors should include chemotherapy and radiation. The overall 5-year survival for this aggressive group is less then 50%. Surgery is rarely beneficial in diffuse large cell lymphoma and the mixed large cell subtypes because the disease is generally disseminated and surgical excision of all disease is not possible or associated with increased morbidity. However, there may be a role for palliative surgical debulking to alleviate obstructive symptoms while the patient is undergoing standard chemotherapy and radiation.